152 related articles for article (PubMed ID: 38447700)
1. Mental health outcomes in patients with moderate to severe psoriasis treated with bimekizumab: Analysis of phase 2/3 randomized trials.
Blauvelt A; Armstrong A; Merola JF; Strober B; de Cuyper D; Peterson L; Davies O; Stark JL; Lebwohl M
J Am Acad Dermatol; 2024 Jul; 91(1):72-81. PubMed ID: 38447700
[TBL] [Abstract][Full Text] [Related]
2. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial.
Papp KA; Merola JF; Gottlieb AB; Griffiths CEM; Cross N; Peterson L; Cioffi C; Blauvelt A
J Am Acad Dermatol; 2018 Aug; 79(2):277-286.e10. PubMed ID: 29609013
[TBL] [Abstract][Full Text] [Related]
3. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials.
Gordon KB; Langley RG; Warren RB; Okubo Y; Stein Gold L; Merola JF; Peterson L; Wixted K; Cross N; Deherder D; Thaçi D
JAMA Dermatol; 2022 Jul; 158(7):735-744. PubMed ID: 35544084
[TBL] [Abstract][Full Text] [Related]
4. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial.
Gordon KB; Foley P; Krueger JG; Pinter A; Reich K; Vender R; Vanvoorden V; Madden C; White K; Cioffi C; Blauvelt A
Lancet; 2021 Feb; 397(10273):475-486. PubMed ID: 33549192
[TBL] [Abstract][Full Text] [Related]
5. Bimekizumab for patients with moderate to severe plaque psoriasis: 60-week results from BE ABLE 2, a randomized, double-blinded, placebo-controlled, phase 2b extension study.
Blauvelt A; Papp KA; Merola JF; Gottlieb AB; Cross N; Madden C; Wang M; Cioffi C; Griffiths CEM
J Am Acad Dermatol; 2020 Nov; 83(5):1367-1374. PubMed ID: 32473974
[TBL] [Abstract][Full Text] [Related]
6. First-in-human randomized study of bimekizumab, a humanized monoclonal antibody and selective dual inhibitor of IL-17A and IL-17F, in mild psoriasis.
Glatt S; Helmer E; Haier B; Strimenopoulou F; Price G; Vajjah P; Harari OA; Lambert J; Shaw S
Br J Clin Pharmacol; 2017 May; 83(5):991-1001. PubMed ID: 27859546
[TBL] [Abstract][Full Text] [Related]
7. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Afach S; Doney L; Dressler C; Hua C; Mazaud C; Phan C; Hughes C; Riddle D; Naldi L; Garcia-Doval I; Le Cleach L
Cochrane Database Syst Rev; 2020 Jan; 1(1):CD011535. PubMed ID: 31917873
[TBL] [Abstract][Full Text] [Related]
8. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial.
Reich K; Papp KA; Blauvelt A; Langley RG; Armstrong A; Warren RB; Gordon KB; Merola JF; Okubo Y; Madden C; Wang M; Cioffi C; Vanvoorden V; Lebwohl M
Lancet; 2021 Feb; 397(10273):487-498. PubMed ID: 33549193
[TBL] [Abstract][Full Text] [Related]
9. Bimekizumab versus Secukinumab in Plaque Psoriasis.
Reich K; Warren RB; Lebwohl M; Gooderham M; Strober B; Langley RG; Paul C; De Cuyper D; Vanvoorden V; Madden C; Cioffi C; Peterson L; Blauvelt A
N Engl J Med; 2021 Jul; 385(2):142-152. PubMed ID: 33891380
[TBL] [Abstract][Full Text] [Related]
10. Bimekizumab versus Adalimumab in Plaque Psoriasis.
Warren RB; Blauvelt A; Bagel J; Papp KA; Yamauchi P; Armstrong A; Langley RG; Vanvoorden V; De Cuyper D; Cioffi C; Peterson L; Cross N; Reich K
N Engl J Med; 2021 Jul; 385(2):130-141. PubMed ID: 33891379
[TBL] [Abstract][Full Text] [Related]
11. Bimekizumab treatment in patients with moderate to severe plaque psoriasis: a drug safety evaluation.
Ruggiero A; Potestio L; Martora F; Villani A; Comune R; Megna M
Expert Opin Drug Saf; 2023; 22(5):355-362. PubMed ID: 37222656
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Kimball AB; Jemec GBE; Sayed CJ; Kirby JS; Prens E; Ingram JR; Garg A; Gottlieb AB; Szepietowski JC; Bechara FG; Giamarellos-Bourboulis EJ; Fujita H; Rolleri R; Joshi P; Dokhe P; Muller E; Peterson L; Madden C; Bari M; Zouboulis CC
Lancet; 2024 Jun; 403(10443):2504-2519. PubMed ID: 38795716
[TBL] [Abstract][Full Text] [Related]
13. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Sbidian E; Chaimani A; Garcia-Doval I; Doney L; Dressler C; Hua C; Hughes C; Naldi L; Afach S; Le Cleach L
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD011535. PubMed ID: 33871055
[TBL] [Abstract][Full Text] [Related]
14. Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: efficacy, safety, pharmacokinetics, pharmacodynamics and transcriptomics from a phase IIa, randomized, double-blind multicentre study.
Oliver R; Krueger JG; Glatt S; Vajjah P; Mistry C; Page M; Edwards H; Garcet S; Li X; Dizier B; Maroof A; Watling M; El Baghdady A; Baeten D; Ionescu L; Shaw S
Br J Dermatol; 2022 Apr; 186(4):652-663. PubMed ID: 34687214
[TBL] [Abstract][Full Text] [Related]
15. Bimekizumab for the treatment of psoriatic disease.
Natsis NE; Gottlieb AB
Expert Opin Biol Ther; 2018 Dec; 18(12):1193-1197. PubMed ID: 30332893
[TBL] [Abstract][Full Text] [Related]
16. Bimekizumab: The First Dual Inhibitor of Interleukin (IL)-17A and IL-17F for the Treatment of Psoriatic Disease and Ankylosing Spondylitis.
Reis J; Vender R; Torres T
BioDrugs; 2019 Aug; 33(4):391-399. PubMed ID: 31172372
[TBL] [Abstract][Full Text] [Related]
17. Bimekizumab in psoriasis: a monocentric study evaluating short- and mid-term effectiveness and safety profile in a real-world setting.
Rompoti N; Stefanaki I; Panagakis P; Vavouli C; Politou M; Papoutsaki M; Befon A; Koutsa F; Lazou E; Koumprentziotis IA; Chasapi V; Stratigos A; Nicolaidou E
Arch Dermatol Res; 2024 Apr; 316(5):133. PubMed ID: 38662223
[TBL] [Abstract][Full Text] [Related]
18. Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials.
Lebwohl MG; Papp KA; Marangell LB; Koo J; Blauvelt A; Gooderham M; Wu JJ; Rastogi S; Harris S; Pillai R; Israel RJ
J Am Acad Dermatol; 2018 Jan; 78(1):81-89.e5. PubMed ID: 28985956
[TBL] [Abstract][Full Text] [Related]
19. Bimekizumab for psoriasis.
Rodrigues MA; Freitas E; Torres T
Drugs Today (Barc); 2022 Jun; 58(6):273-282. PubMed ID: 35670705
[TBL] [Abstract][Full Text] [Related]
20. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
Ali Z; Matthews R; Al-Janabi A; Warren RB
Expert Rev Clin Immunol; 2021 Oct; 17(10):1073-1081. PubMed ID: 34384327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
